**SBA PPP Tracker: Community Banks Shine (v1)**

**Summary**

In our first edition of our SBA Paycheck Protection Program (PPP) Tracker, we provide company level detail on PPP participation based on disclosures provided thus far [excel file here](https://example.com). With 4,975 lenders approving loans in the program, we expect most banks are involved with making PPP loans, and we plan to update our tracker throughout earnings as companies (both banks and nonbanks) provide more color on their involvement. Additionally, we provide an update on PPP lending based on statistics released by the SBA as of midday Thursday, 4/16 [here](https://example.com).

- **PPP Tracker by Company** - We are launching our PPP tracker excel file [here](https://example.com) that details SBA PPP volumes and participation. In our first iteration, we are including lenders who have released information on their involvement in PPP. That said, with 4,975 lenders approving loans in the program through midday on 4/16, we believe most banks are involved, as are nonbank lenders that were already active SBA, as well as several recent fintech additions to PPP. We intend to continue updating this product through earnings season as companies disclose more information about their involvement.

- **High Level Lender Breakdown** - According to a tweet on Friday by SBA Administrator Carranza, about 60% of loans were processed by banks <$10B in assets. The smallest banks were also very active, with banks under $1B in assets representing almost 20% of loans processed. To put these numbers in perspective, banks <$10B in assets and <$1B in assets represented about 16% and 6% of PPP loan approvals, respectively, as of 2019. To us, this data suggests that community banks are outperforming when it comes to PPP lending. Data provided by the SBA shows that no lender represents >5% of approval amount (p6, [here](https://example.com)). JPM confirmed that it was the largest lender at $14.1B (4% of approval amount) per a Bloomberg article.

- **Loan Size Characteristics** - Some of the high-balance PPP loans have captivated the attention of the media (e.g., Ruth's Chris [RUTH] and J. Alexander [JAX] both got 2 loans each totaling $20mm and $15.1mm, respectively, while Potbelly [PBPB], ShakeShack [SHAK], Taco Cabana [FRGI], Quantum Corp. [QMCO], and Hallador Energy [HNRG] all got the max $10mm according to SEC filings). That said, most PPP loans are much smaller. As of midday Thursday (4/16), PPP loan approvals totaled $342B over 1.66mm loans, implying an average loan size of $206K. Nearly 90% of loan approvals were under $350K (32% of $ amounts approved) while less than 2% of loans were >$2mm (28% of $ amounts approved).

- **Top Industries** - The largest industries by approvals (all >10% of approval amounts) include: construction (13.1%); professional, scientific, and technical services (12.7%); manufacturing (12.0%); and health care and social assistance (11.7%). There has been a lot of consternation as to why construction ranks at the top, rather than accommodation/food services or retail trade (#5 and #6 at 8.9% and 8.6%, respectively), which are some of the heaviest hit in the COVID-19 panic. However, the top industries do not necessarily surprise us, and believe any of the following could explain this distribution: (i) PPP loan allocations are not necessarily based on need; (ii) it's possible that construction borrowers had deeper banking relationships, and these requests may have been prioritized over other borrowers; and (iii) the PPP structure - whereby 75% of the loan forgiveness amount must be allocated towards payroll - is not particularly helpful to restaurants, where revenue has dropped precipitously and payroll is a smaller percentage of overhead costs.

- **Loan Fees** - As a reminder, the SBA pays loan fees to lenders in the program (5% for loans <$350K, 3% for loans $350K-$2mm, 1% for loans $2mm+). We have received a lot of questions on how these fees flow throw the income statement. Based on early disclosures, it is our understanding that these fees will come through interest income over the life of the loan for banks, with the assumption that the majority of these loans will be forgiven and thus most fees will be realized in the first quarter or two. However, we continue to monitor commentary about the accounting treatment of these fees.

**Glossary of Terms**

Keefe, Bruyette & Woods, Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Please refer to important disclosures and analyst certification information on pages 2 - 5.
IMPORTANT DISCLOSURES

RESEARCH ANALYST CERTIFICATION: We, Kelly Motta, CFA and KBW Research, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject companies and their securities. We also certify that we have not been, and will not be receiving direct or indirect compensation in exchange for expressing the specific recommendation in this report.

Analysts’ Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking.

The recommendations contained in this report were produced at 19 April 2020 21:40 EDT and disseminated at 19 April 2020 21:40 EDT

For disclosures pertaining to recommendations or estimates made on a security mentioned in this report, please see the most recently published company report or visit our global disclosures page on our website at https://www.kbw.com/capabilities/research/disclosures/ or see the section below titled “Disclosure Information” for further information on how to obtain these disclosures.

AFFILIATE DISCLOSURES

This report has been prepared by Keefe, Bruyette & Woods, Inc. (“KBWI”) and/or its affiliate Stifel Nicolaus Europe Limited (“SNEL”), also trading as Keefe, Bruyette & Woods Europe (“KBW Europe”); collectively “KBW”. Both KBWI and KBW Europe are affiliates of Stifel Financial Corp. KBWI is regulated by Financial Industry National Regulatory Authority (“FINRA”) and the United States Securities and Exchange Commission (“SEC”), is a member of New York Stock Exchange, and its headquarters is located at 787 7th Avenue, New York, NY 10019. Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, is incorporated in England and Wales under company no. 03719559, holds its registered office at 4th Floor, 150 Cheapside, London EC2V 6ET and is authorized and regulated by the U.K. Financial Conduct Authority (FCA) under registration no. 190412 and is a member of the London Stock Exchange. Disclosures in the “Company Specific Disclosures” section referencing KBW include one or all affiliated entities unless otherwise specified. Such affiliates shall include (i) Stifel, Nicolaus & Company, Incorporated (“SNC”) which is a U.S. broker-dealer registered with SEC and a member of FINRA; (ii) our MainFirst affiliates (collectively “MAINFIRST”): MainFirst Bank AG, which is regulated by the German Federal Financial Services Authority (Bundesanstalt für Finanzdienstleistungsaufsicht; “BaFin”), MainFirst Schweiz AG, which is regulated by the Eidgenössische Finanzmarktaufsicht (“FINMA”), and MainFirst Securities US Inc. which is a U.S. broker-dealer registered with the SEC and a member of FINRA; and (iii) Stifel Nicolaus Canada. Incorporated ("Stifel Canada"), which is authorised and regulated by Investment Industry Regulatory Organization of Canada (“IIROC”), and also trades under the names “Stifel GMP” and/or “Stifel First Energy”.

Registration of non-U.S. Analysts: Any non-U.S. Research Analyst employed by a non-U.S. affiliate of KBWI contributing to this report is not registered/qualified as research analyst with FINRA and/or the NYSE and may not be an associated person of KBWI and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Disclosure Information: For current company-specific disclosures, please write to one of the KBW entities: For U.S. Research: Keefe, Bruyette & Woods, Inc. Research Department, 787 7th Avenue, 4th Floor, New York, NY 10019. For European Research: The Compliance Officer, Stifel Nicolaus Europe Limited, 4th Floor, 150 Cheapside, London EC2V 6ET. Or visit our website at https://www.kbw.com/capabilities/research/disclosures/. KBW has arrangements in place to manage conflicts of interest including information barriers between the Research Department and certain other business groups. As a result, KBW does not disclose certain client relationships with, or compensation received from, such companies in its research reports.

* Distribution of Ratings/IB Services

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Outperform</td>
<td>210</td>
<td>35.29</td>
<td>48</td>
<td>22.86</td>
<td>86</td>
<td>40.95</td>
</tr>
<tr>
<td>Market Perform</td>
<td>313</td>
<td>52.61</td>
<td>62</td>
<td>19.81</td>
<td>123</td>
<td>39.30</td>
</tr>
<tr>
<td>Suspended</td>
<td>32</td>
<td>5.38</td>
<td>1</td>
<td>3.12</td>
<td>7</td>
<td>21.88</td>
</tr>
<tr>
<td>Underperform</td>
<td>38</td>
<td>6.39</td>
<td>5</td>
<td>13.16</td>
<td>14</td>
<td>36.84</td>
</tr>
<tr>
<td>Covered - Not Rated</td>
<td>2</td>
<td>0.34</td>
<td>0</td>
<td>0.00</td>
<td>0</td>
<td>0.00</td>
</tr>
</tbody>
</table>

*Distribution of Ratings relates to all KBW branded research. **IB services relate to global investment banking services in the past 12 months. ***Material services relate to both global investment banking services and other non-investment banking services in the past 12 months, in accordance with Sections A and B of Annex I of Directive 2014/65/EU.

Explanation of Ratings: KBW Research Department provides three core ratings: Outperform, Market Perform, and Underperform, and three ancillary ratings: Suspended, Restricted, and Covered-Not Rated. For purposes of FINRA Rule 2241, Outperform is classified as a Buy, Market Perform is classified as a Hold, and Underperform is classified as a Sell. Suspended indicates that KBW’s investment rating and/or target price have been
temporarily suspended due to applicable regulations and/or KBW policies. Restricted indicates that KBW is precluded from providing an investment rating or price target due to the firm’s role in connection with a merger or other strategic financial transaction. Covered-Not Rated indicates that KBW is not providing an investment rating and/or price target due to the lack of publicly available information and/or its inability to adequately quantify the publicly available information to sufficiently produce such metrics.

North American Stocks and European Stocks are rated based on the share price upside to target price relative to the relevant sector index performance on a 12-month horizon. Outperform rated stocks have a greater than 10 percentage point (“pp”) relative performance versus the sector, Market Perform rated stocks between +10pp to -10pp relative performance versus the sector, and Underperform rated stocks a lower than 10pp relative performance versus the sector. The 12-month price target may be determined by the stock’s fundamentally driven fair value and/or other factors (e.g., takeover premium or illiquidity discount).

KBW Model Portfolio: “Model Portfolio Buy” - Companies placed on this list are expected to generate a total rate of return (percentage price change plus dividend yield) of 10% or more over the next 3 to 6 months. "Model Portfolio Sell" - Companies placed on this list are expected to generate a total rate of return (percentage price change plus dividend yield) at or below -10% over the next 3 to 6 months.

The purpose of the Model Portfolio is to inform institutional investors of KBWI’s short-term (as described above) outlook for a particular industry sector. The Portfolio is not available for purchase or sale, cannot be duplicated as shown, is hypothetical and is for illustrative purposes only. For a more detailed description of the selection criteria and other specifics related to the construction of the Model Portfolio, please refer to the January 5, 2010 Model Portfolio Primer and/or contact your KBWI representative for more information.

The Model Portfolio should be viewed as a short-term outlook of a particular industry sector, not as individual security recommendations. The Model Portfolio uses a three-to-six-month time horizon and should not be considered when making longer term investments. KBWI Research publishes research with a 12-month outlook on each issuer of securities contained in the Model Portfolio. Investors who are interested in a particular security should request KBWI Research’s coverage of such securities by contacting your KBWI representative. KBW research contains analyses of fundamentals underlying each issuer.

KBW’s long-term recommendations may differ from recommendations made for the Model Portfolio. These differences are the result of different time horizons—KBWI research has a 12-month outlook and the Model Portfolio has a three-to-six-month outlook.

Although the model portfolio is based upon actual performance of actual investments, KBWI did not recommend that investors purchase this combination—or hypothetical portfolio—of investments during the time period depicted here. As this hypothetical portfolio was designed with the benefit of hindsight, the choice of investments contained in it reflects a subjective choice by KBWI. Accordingly, this hypothetical portfolio may reflect a choice of investments that performed better than an actual portfolio, which was recommended during the depicted time frame, would have performed during the same time period. Moreover, unlike an actual performance record, these results do not represent actual trading wherein market conditions or other risk factors may have caused the holder of the portfolio to liquidate or retain all or part of the represented holdings.

Stifel/KBW Income Opportunity List, Stifel/KBW Analyst Select List, and Stifel/KBW Select Income Opportunity—The Crossovers List: These lists include companies that analysts believe have the most attractive risk-adjusted return potential over the next 12 months, or, in the case of the Stifel/KBW Income Opportunity Ideas List, have yield in excess of 2%. In some cases, analysts who cover more than one sub-sector may have more than one name on the list.

Other Research Methods: Please be advised that KBW provides to certain customers on request specialized research products or services that focus on covered stocks from a particular perspective. These products or services include, but are not limited to, compilations, reviews, and analysis that may use different research methodologies or focus on the prospects for individual stocks as compared to other covered stocks or over differing time horizons or under assumed market events or conditions.

OTHER DISCLOSURES

Indexes: The following indexes: U.S.: KBW Nasdaq Bank Index (BKX), KBW Nasdaq Insurance Index (KIX), KBW Nasdaq Capital Markets Index (KRX), KBW Nasdaq Regional Banking Index (KRX), KBW Nasdaq Property & Casualty Index (KRX), KBW Nasdaq Financial Technology Index (KFTX), KBW Nasdaq Premium Yield Equity REIT Index (KYYX); KBW Nasdaq Financial Sector Dividend Yield Index (KDX); and Global: KBW Nasdaq Global Bank Index (GBKX), are the property of KBWI and Nasdaq.

KBWI and Nasdaq do not guarantee the accuracy and/or completeness of the indexes, make no express or implied warranties with respect to the indexes and shall have no liability for any damages, claims, losses, or expenses caused by errors in the index calculation. KBWI and Nasdaq make no representation regarding the advisability of investing in options on the Index. Past performance is not necessarily indicative of future results.

ETFs—Important Disclosures: The shares (“Shares”) of ETFs are not sponsored, endorsed, sold, or promoted by KBWI. KBWI makes no representation or warranty, express or implied, to the owners of the Shares or any member of the public regarding the advisability of investing in securities generally or in the Shares particularly or the ability of its Indexes to track general stock market performance. The only relationship of KBWI to Invesco Capital Management LLC is the licensing of certain trademarks and trade names of KBWI and its Indexes which are determined, composed, and calculated by KBWI without regard to Invesco Capital Management LLC, the fund, or the Shares. Additionally, KBWI and The NASDAQ OMX Group, Inc. (“Nasdaq”) are parties to an agreement (the “Nasdaq Agreement”) whereby KBWI has given Nasdaq the power and authority to license certain trademarks and trade names of KBW and its Indexes, including Invesco UK Services Limited and potential future Licensees. KBWI has no obligation to take the needs of Invesco Capital Management LLC or any other current or future Licensee or the owners of the shares into consideration in determining, composing, or calculating the Indexes. KBWI is not responsible for and has not participated in any determination or
calculation made with respect to issuance or redemption of the Shares. KBWI has no obligation or liability in connection with the administration, marketing, or trading of the Shares.

**Compensation.** KBWI and Invesco Capital Management LLC are parties to an index licensing agreement wherein KBWI licenses its Indexes to Invesco Capital Management LLC and KBWI receives as compensation payments based on the amount of assets under management in the ETFs (which the licensed Indexes underlie) and which may be recommended in this report. Pursuant to the Nasdaq Agreement, KBWI similarly receives as compensation payments based on the amount of assets under management in any Licensee ETFs (which the licensed Indexes underlie) and which may or may not also be recommended in this report.

**ETF and Index Reports.** The author of index and related ETF reports is the Director of KBWI’s Research Department, who is also the head of the KBWI Index Committee. This Index Committee selects index components for the indexes upon which the recommended ETFs are based.

**ETF Risks.** There are risks involved with investing in ETFs, including possible loss of money. ETFs may not always trade or price as expected. Generally, security classifications used in calculating allocation tables are as of the last trading day of the previous month. ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Diversification does not ensure a profit and may not protect against loss in declining markets. Investors should refer to the individual ETF prospectus for a more detailed discussion of the specific risks and considerations for an individual ETF.

Investing in a single sector may be subject to more volatility than funds investing in a diverse group of sectors. Brokerage commissions and ETF expenses will reduce returns. In general, ETFs can be expected to move up or down in value with the value of the applicable index. Although ETFs may be bought and sold on the exchange through any brokerage account, ETFs are not individually redeemable from the Fund. Investors may acquire ETFs and tender them for redemption through the Fund in Creation Unit Aggregations only, please see the prospectus (link below) for more details. Shares are not actively managed and are subject to risks including those regarding short selling and margin maintenance requirements. Past performance is not necessarily indicative of future results.

An investor should consider the Funds’ investment objectives, risks, charges, and expenses carefully before investing. This and other information can be found in their prospectuses. Not all ETFs may be suitable for retail investors. Individual ETFs may not be available for sale in all jurisdictions. For this and more complete information about the U.S Funds, call Invesco at 1-800-983-0903 or visit https://www.invesco.com/ETFs for a prospectus.

For more complete information about the non-U.S. Funds, investors should contact Invesco at https://etf.invesco.com/gb/private/en/product/invesco-kbw-nasdaq-fintech-ucits-etf-acc/trading-information for a prospectus. The prospectus should be read carefully before investing.

Shares of the ETFs funds are not guaranteed or insured by the FDIC or by another governmental agency; they are not obligations of the FDIC nor are they deposits or obligations of or guaranteed by KBWI or Invesco Capital Management LLC. ETFs are distributed by Invesco Distributors, Inc. the distributor of the Invesco Exchange-Traded Fund Trust II.

**General Risk Disclosure:** Investments in securities or financial instrument involve numerous risks which may include market risk, counterparty default risk, liquidity risk and exchange rate risk. No security or financial instrument is suitable for all investors, and some investors may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in this communication. The securities of some issuers may not be subject to the audit and reporting standards, practices and requirements comparable to those companies located in the investor’s local jurisdiction. Where net dividends to ADR investors are discussed, these are estimated, using withholding tax rate conventions, and deemed accurate, but recipients should always consult their tax advisor for exact dividend computations.

**COUNTRY-SPECIFIC AND JURISDICTIONAL DISCLOSURES**

**United States:** This report is being distributed in the U.S. by KBWI. Where the report has been prepared by a non-U.S. affiliate, KBWI accepts responsibility for its contents.

**U.K. and European Economic Area (EEA):** This report is issued and approved for distribution in the EEA by Stifel Nicolaus Europe Limited, also trading as Keefe, Bruyette & Woods Europe, which is regulated in the United Kingdom by the Financial Conduct Authority (FCA). Our European Policy for Managing Research Conflicts of Interest is available at www.stifel.com/institutional/ImportantDisclosures.

To access a table of all rating and price target changes in the preceding 12 months for stocks under KBW coverage, please click here: https://kbw3.bluematrix.com/sellside/MAR.action

**Canadian Distribution:** Research produced by KBW is distributed in Canada by KBW in reliance on the international dealer exemption. This material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a “permitted client” as defined under applicable Canadian securities law.

**Republic of South Africa:** Research produced by Stifel Nicolaus Europe Limited (SNEL), also trading as Keefe, Bruyette & Woods Europe, is distributed by SNEL to “Clients” as defined in FSCA FAIS Notice 20 of 2018 (the “FAIS Notice”) issued by the Financial Services Conduct Authority. Research distributed by SNEL is pursuant to an exemption from the licensing requirements under Section 7(1) of the Financial Advisory and Intermediary Services Act, 2002.

In jurisdictions where KBW is not already licensed or registered to trade securities, transactions will only be affected in accordance with local securities legislation which will vary from jurisdiction to jurisdiction and may require that a transaction is carried out in accordance with applicable exemptions from registration and licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a representative of the KBW entity in their regional jurisdiction except where governing law permits otherwise. U.S. customers wishing to effect a transaction should do so by contacting a representative of KBWI.

**ONLY DISTRIBUTE UNDER REGULATORY LICENSE**